Save 20% on your next Cambridge Bioethics and Law online purchase
Page URL: https://www.bionews.org.uk/page_93531

Gene therapy shows early success in Parkinson's trial

16 April 2012
Appeared in BioNews 652

A woman with Parkinson's disease is reportedly able to write again for the first time in 15 years after receiving pioneering gene therapy at Addenbrooke's Hospital, Cambridge. Mrs Shelia Roy took part in an early stage clinical trial of ProSavin - a treatment developed by biopharmaceutical company, Oxford BioMedica.

Roy was diagnosed with Parkinson's 17 years ago in her mid 40s. During the trial, a modified virus was injected into Roy's brain containing coding instructions for dopamine-producing proteins. Patients with Parkinson's have a lack of dopamine in the brain which leads to symptoms including tremors and an inability to co-ordinate movement. This can make even everyday tasks - like writing - very difficult.

Speaking of her experience, Roy said: 'Parkinson's disease changes the ability and capability of the individual affected. You lose confidence, dignity and hope. The [treatment] has given me hope'. Although Roy's experience is an encouraging result, scientists have warned that it may still be at least five years before ProSavin becomes available.

Dr Philip Buttery, from the Cambridge Centre for Brain Repair, University of Cambridge, told Sky News that while the treatment was still in its early stages the results look promising. 'It seems to be having an overall beneficial effect in smoothing out people's days, probably allowing a slight dose reduction in medication, and in some patients a better sleep pattern and a better quality of life for all', he said.

Roy took part in a small Phase I/II clinical trial with 14 other people with mid-stage Parkinson's who were no longer responding well to existing treatments. Five additional patients in the UK received a high dose of ProSavin. Although the trial was designed to test the dose needed and the safety of the treatment, when assessed these patients showed an average 29 percent improvement in motor function over a three month period. Larger studies are now needed to confirm these results.

Commenting on the results, Dr Kieran Breen, director of research and innovation at the charity Parkinson's UK, said: 'Gene therapies hold great promise for people with Parkinson's in the future, as they could mean an end to the daily regime of drugs that most people with the condition currently face'.

He added: 'In addition to ProSavin, there are three other gene therapy trials under way at the moment. So far all the therapies appear to be safe - now the challenge is to see whether they are more effective than the medications we already have for Parkinson's'.

SOURCES & REFERENCES
Gene therapy helps woman to write
Press Association |  12 April 2012
New hope for Parkinson's disease
ITV News |  13 April 2012
Parkinson's disease sufferer can write for the first time in 15 years thanks to new gene therapy
Mail Online |  12 April 2012
Revolutionary New Treatment For Parkinson's
Sky News |  12 April 2012
RELATED ARTICLES FROM THE BIONEWS ARCHIVE
10 January 2014 - by Dr Kimberley Bryon-Dodd 
Patients in a clinical trial to treat Parkinson's disease with a form of gene therapy have showed signs of significant improvements in their motor-function, according to a report published in the Lancet...
7 May 2013 - by Siobhan Chan 
Gene therapy will be used to treat heart failure for the first time in the UK, in clinical trials being launched by the British Heart Foundation...
25 March 2013 - by Helen Brooks 
An experimental approach to treating Parkinson's disease may need to be reconsidered following evidence suggesting that it may make patients worse...
5 November 2012 - by Dr Lucy Spain 
The European Medicines Agency (EMA) has approved Glybera, a gene therapy to treat a rare genetic condition, lipoprotein lipase deficiency (LPLD), for sale across Europe. Glybera is the first gene therapy to be approved for the Western market and offers the first therapeutic treatment for people with LPLD....
10 September 2012 - by Holly Rogers 
Scientists have restored the sense of smell in mice using a gene therapy designed to repair the cilia - hair-like formations on nasal cells that are important in olfaction...
13 February 2012 - by George Frodsham 
Human brain cells with Parkinson's disease have been successfully grown in a Petri dish, allowing researchers to study them in unprecedented detail. Researchers used a technique in which skin cells are transformed into induced pluripotent stem cells, which can then be made to change into any cell type – in this case, neurons...
28 March 2011 - by Alison Cranage 
For the first time, gene therapy has shown promise for people with severe Parkinson's disease. Results from a proof of concept clinical trial in the US were published in the journal Lancet Neurology...
19 October 2009 - by Alison Cranage 
A gene therapy for Parkinson's disease that has been tested on monkeys is showing promising early results in a small-scale trial on humans. French researchers reported their findings in the new journal Science Translational Medicine last week....
14 April 2008 - by Evelyn Harvey 
Nerve tissue derived from stem cells made from reprogrammed skin developed into normal brain tissue and relieved symptoms of Parkinson's disease in rats, in a study published in the journal Proceedings of the National Academy of Sciences of the USA (PNAS) last week. Scientists at the Whitehead...
HAVE YOUR SAY
Log in to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.